title: [Combination of chemotherapy (vindesine, lomustine, cisplatin, cyclophosphamide) and thoracic radiotherapy in nonresectable non-small cell bronchial carcinoma: final results of a phase II clinical trial].
abstract: Seventy-five patients with locally advanced non small cell lung carcinoma were entered in a phase II study combining chemotherapy (vindesine, lomustine, cisplatin and cyclophosphamide) and radical thoracic radiotherapy delivering a total dose of 60-65 Gy. Patients were regularly assessed by radiological and fiberoptic bronchoscopy examinations in order to evaluate local control. An objective response was observed in 22 patients (29%) after initial chemotherapy (2 complete remissions and 20 partial responses). The complete response rate after the combined schedule was 30%. Toxicity of this combination was acceptable. Median survival was 13.5 months. Actuarial risk of developing distant metastases at 3 years was 60%. However, the main cause of failure was local with 80% of uncontrolled or recurrent thoracic tumor in the first 2 years of follow-up. The present study shows that local control remains a major problem in the management of patients with inoperable non metastatic non small cell lung cancer.
authors.affiliation: Institut Gustave-Roussy, Villejuif, France.
authors.forename: E
authors.initials: E
authors.lastname: Nasr
authors.forename: B
authors.initials: B
authors.lastname: Pellae-Cosset
authors.forename: R
authors.initials: R
authors.lastname: Arriagada
authors.forename: T
authors.initials: T
authors.lastname: Le Chevalier
authors.forename: P
authors.initials: P
authors.lastname: Baldeyrou
authors.forename: P
authors.initials: P
authors.lastname: Ruffie
authors.forename: H
authors.initials: H
authors.lastname: de Cremoux
authors.forename: M
authors.initials: M
authors.lastname: Martin
authors.forename: M
authors.initials: M
authors.lastname: Tarayre
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002283:Carcinoma, Bronchogenic / Q000628:therapy*; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011879:Radiotherapy Dosage; D016019:Survival Analysis; D014751:Vindesine / Q000008:administration & dosage
chemical_list: D008130:Lomustine; D003520:Cyclophosphamide; D002945:Cisplatin; D014751:Vindesine
vernacular_title: Association chimiothérapie (vindésine, lomustine, cisplatine, cyclophosphamide)--radiothérapie thoracique dans les carcinomes bronchiques non à petites cellules inopérables: résultats définitifs d'un essai phase II.